About Tarlatamab
Underlined terms can be clicked for more information.
Underlined terms can be clicked for more information.
Tarlatamab is a type of drug called a bispecific T-cell engager, or BiTE® molecule, that has two key parts: a part that attaches to your T-cells, a type of immune cell, and a part that attaches to the cancer cells.
Tarlatamab is a type of immunotherapy that works differently than standard chemotherapy. It is designed to help the body's immune cells find, attach to, and attack cancer cells.
Tarlatamab moves throughout the body finding T-cells and cancer cells
Tarlatamab attaches to a T-cell and a cancer cell and brings them close together
Tarlatamab enables the T-cell to attack the cancer cell, which stimulates the T-cell to multiply and attack other cancer cells
For patients with extensive-stage SCLC receiving their first course of treatment. Patients with prior limited-stage SCLC may qualify.
For patients with limited-stage SCLC who have completed chemotherapy and radiation therapy without progression.
If you are a physician or another healthcare professional interested in learning more about a tarlatamab clinical trial or referring a patient, please contact an Amgen Medical Information Healthcare Professional.
Where can I get more information?
To determine if you may be eligible for a clinical trial for tarlatamab, talk to your doctor or contact an Amgen Medical Information Healthcare Professional.